BAJAJ BROKING
Lupin's Somerset, NJ facility, inspected by the FDA from May 7 to May 17, 2024, received Form-483 with six observations. The company's Q4 FY24 saw a 41.38% net profit drop to ₹359.43 crore on a 3.64% revenue decline to ₹4895.11 crore.
Lupin Limited, a pharmaceutical company known for its innovation, underwent a pre-approval inspection by the US Food and Drug Administration (FDA) at its manufacturing facility in Somerset, New Jersey.
Explore: Lupin Limited Share Price
The inspection was carried out from May 7 to May 17, 2024, and resulted in the issuance of a Form-483 by the FDA. This form highlighted six observations made by the inspectors regarding potential regulatory violations.
Lupin promptly responded to the FDA's observations, pledging to address them comprehensively. As per regulatory requirements, the company will provide a detailed corrective action plan within the specified timeframe to ensure compliance with FDA regulations.
Additional Read: Share Market News
In the fourth quarter of FY24, Lupin witnessed a significant decline in its consolidated net profit, plummeting by 41.38% to ₹359.43 crore. Additionally, the company's revenue from operations saw a decrease of 3.64% to ₹4895.11 crore compared to Q4 FY23.
Lupin disclosed the outcome of the FDA inspection in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This communication was made to the Bombay Stock Exchange (BSE), ensuring transparency and adherence to regulatory norms.
Disclaimer: Investments in the securities market are subject to market risk, read all related documents carefully before investing.
This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For All Disclaimers Click Here: https://bit.ly/3Tcsfuc
Share this article:
Gold Rate Today | 15 January 2025 | Gold Price in India
15 Jan, 2025 | 40 Min. read
Delhi Court Discharges JSW Steel in Corruption Case; HC Clears Monnet Takeover
15 Jan, 2025 | 2 Min. read
IRFC Emerges L1 Bidder to Finance ₹3,167 Crore for Banhardih Coal Block
15 Jan, 2025 | 2 Min. read
Cipla’s Tax Demand Reduced to ₹559.18 Crores After Revision
15 Jan, 2025 | 2 Min. read
Govt Plans 5-6% Hike in Highway Budget for FY26 After FY25 Slump
15 Jan, 2025 | 2 Min. read
Rikhav Securities IPO- Key Objective & Deep Analysis
15 Jan, 2025 | 5 Min. read
Landmark Immigration IPO- Key Objective & Deep Analysis
15 Jan, 2025 | 5 Min. read
HCL Tech expands partnership with Microsoft to transform contact centres
14 Jan, 2025 | 2 Min. read
BEL secures new orders worth Rs 561 crore, boosting FY25 order book
14 Jan, 2025 | 2 Min. read
ITI Ltd secures Rs 64 crore contracts for Wi-Fi and CCTV systems
14 Jan, 2025 | 2 Min. read
JSW Energy secures LoI for 3.6 GW KSK Mahanadi power plant
14 Jan, 2025 | 2 Min. read
Biocon Biologics’ Johor Bahru Facility Receives FDA VAI Classification
13 Jan, 2025 | 2 Min. read
RBI Launches ULI: Transforming Loan Access
August 27, 2024 | 4 Min. read
Textile Sector in India
September 20, 2024 | 5 Min. read
List of IPOs with DRHPs Filed
November 30, 2023 | 3 Min. read
Aditya Birla Group
September 28, 2023 | 10 Min. read
Bajaj Housing Finance Ltd IPO: Things Smart Investors Need to Know
September 05, 2024 | 4 Min. read
Budget Stock Ideas 2024-2025 | Stocks to Buy Today
July 24, 2024 | 4 Min. read
IPO Eligibility Criteria : Full Details
March 15, 2024 | 6 Min. read
What Is the Lock-In Period in IPOs?
October 18, 2023 | 6 Min. read
Godfrey Phillips Announces 2:1 Bonus Shares
September 16, 2024 | 7 Min. read
Jindal Group- A Comprehensive Analysis
September 27, 2024 | 7 Min. read
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading